GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Cyclically Adjusted Price-to-FCF

Exelixis (Exelixis) Cyclically Adjusted Price-to-FCF : 40.91 (As of Apr. 29, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Cyclically Adjusted Price-to-FCF?

As of today (2024-04-29), Exelixis's current share price is $23.73. Exelixis's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.58. Exelixis's Cyclically Adjusted Price-to-FCF for today is 40.91.

The historical rank and industry rank for Exelixis's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

EXEL' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 34.86   Med: 47.43   Max: 296
Current: 41.2

During the past years, Exelixis's highest Cyclically Adjusted Price-to-FCF was 296.00. The lowest was 34.86. And the median was 47.43.

EXEL's Cyclically Adjusted Price-to-FCF is ranked better than
60.78% of 102 companies
in the Biotechnology industry
Industry Median: 54.05 vs EXEL: 41.20

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Exelixis's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $-0.008. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.58 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exelixis Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Exelixis's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Cyclically Adjusted Price-to-FCF Chart

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 99.22 43.72 41.71

Exelixis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.72 45.89 38.91 40.16 41.71

Competitive Comparison of Exelixis's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Exelixis's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Exelixis's Cyclically Adjusted Price-to-FCF falls into.



Exelixis Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Exelixis's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=23.73/0.58
=40.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Exelixis's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.008/129.4194*129.4194
=-0.008

Current CPI (Dec. 2023) = 129.4194.

Exelixis Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.378 99.695 -0.491
201406 -0.284 100.560 -0.366
201409 -0.298 100.428 -0.384
201412 -0.256 99.070 -0.334
201503 -0.230 99.621 -0.299
201506 -0.137 100.684 -0.176
201509 -0.157 100.392 -0.202
201512 -0.155 99.792 -0.201
201603 0.684 100.470 0.881
201606 -0.114 101.688 -0.145
201609 -0.023 101.861 -0.029
201612 0.293 101.863 0.372
201703 0.220 102.862 0.277
201706 0.013 103.349 0.016
201709 0.117 104.136 0.145
201712 0.114 104.011 0.142
201803 0.220 105.290 0.270
201806 0.199 106.317 0.242
201809 0.479 106.507 0.582
201812 0.326 105.998 0.398
201903 0.506 107.251 0.611
201906 0.414 108.070 0.496
201909 0.233 108.329 0.278
201912 0.479 108.420 0.572
202003 0.168 108.902 0.200
202006 0.298 108.767 0.355
202009 0.038 109.815 0.045
202012 0.059 109.897 0.069
202103 0.081 111.754 0.094
202106 0.499 114.631 0.563
202109 0.214 115.734 0.239
202112 0.249 117.630 0.274
202203 0.440 121.301 0.469
202206 0.058 125.017 0.060
202209 0.314 125.227 0.325
202212 -0.119 125.222 -0.123
202303 0.110 127.348 0.112
202306 0.347 128.729 0.349
202309 0.074 129.860 0.074
202312 -0.008 129.419 -0.008

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exelixis  (NAS:EXEL) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Exelixis Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Exelixis's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (Exelixis) Business Description

Industry
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
Patrick J. Haley officer: Sr. Vice President, Commercial 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel officer: EVP and General Counsel 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson director 590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab officer: CSO/EVP Disc & Trans Research EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson officer: EVP Prod Dev & Med Aff & CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner officer: EVP and CFO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp director, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski director SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber director 3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum director C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb officer: EVP, Discovery Research & CSO PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste director 515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083

Exelixis (Exelixis) Headlines